
    
      This study will be a Phase 1 randomized double-blind, placebo controlled multi dose study in
      up to 144 adult healthy volunteers. The safety, tolerability and impact on the microbiome
      following intake of oral dose of JNJ-67670187 for up to 14 days will be evaluated.
    
  